Skye Bioscience, Inc. (SKYE)
CIK 1516551 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 35.1M shares as of May 8, 2026 (10-Q). Share count fell from 971.5M to 12.3M between Aug 4, 2023 and Nov 12, 2023, a pattern consistent with a reverse split (roughly 1-for-79); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| January2024 PIPE Financing Pre Funded Warrants | 1.8M | not tagged | — | FV $1.4M |
| Two Thousand Sixteen Common Stock Warrants To Service Providers | not tagged | $287.5 | — | — |
| Two Thousand and Twenty One Inducement Warrants | not tagged | $37.5 | — | — |
| Two Thousand and Twenty One Inducement Warrants To Placement Agent | not tagged | $47 | — | — |
| Two Thousand and Twenty One Common Stock Warrants | not tagged | $22.5 | — | — |
| Two Thousand and Twenty Pre Funded Warrants | not tagged | $27.5 | — | — |
| August2023 Convertible Note Common Stock Warrants | not tagged | $5.16 | — | — |
| August2023 PIPE Financing Common Stock Warrants | not tagged | $5.16 | — | — |
| January2024 Pre Funded Warrants Common Stock | not tagged | $0.001 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 0 underlying shares, as reported Feb 16, 2023 (10-Q).
Reported exercise price: $25 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $2.0M as of Mar 31, 2019.
Rough fully diluted estimate: 35.1M = 35.1M O/S + 0 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed May 11, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 35.1M | May 8, 2026 |
| + January2024 PIPE Financing Pre Funded Warrants (if exercised) | 1.8M | Mar 11, 2026 |
| Fully diluted estimate | 36.9M | +5.0% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 0 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full SKYE workspace